查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048181

安德森-塔維爾症候群市場 - 全球產業規模、佔有率、趨勢、機會、預測：按疾病類型、分銷管道、地區和競爭格局分類，2021-2031年

Andersen-Tawil Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計安德森-塔維爾症候群的全球市場規模將從 2025 年的 27.8 億美元成長到 2031 年的 42.5 億美元，複合年成長率為 7.33%。

該市場涵蓋基因檢測服務（主要集中於檢測KCNJ2基因突變）以及治療性介入，例如抗心律不整藥物和植入式心臟整流去顫器（ICD）。推動這一成長的關鍵因素包括：次世代定序技術的顯著進步提高了診斷準確性；以及在健全的法規結構支持下，孤兒藥研發投入的增加。這些根本性的成長要素代表著在識別和管理患者群體方面持續的改進，而非短期趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 27.8億美元
市場規模：2031年 42.5億美元
複合年成長率：2026-2031年 7.33%
成長最快的細分市場 網路藥房
最大的市場 北美洲

儘管市場有所成長，但仍面臨許多挑戰，尤其是較高的臨床誤診率。這個問題源於該疾病症狀繁多，掩蓋了市場的真實規模，並延誤了患者接受必要治療的時間。準確評估患者風險的挑戰仍然是阻礙治療方法廣泛應用的主要障礙。歐洲心臟學會的數據顯示，到2025年，約有11%的安德森-塔維爾症候群患者會出現危及生命的心律不整或需要使用醫療設備介入。這凸顯了對更精準的診斷和個人化治療策略的迫切需求。

市場促進因素

由於基因組定序技術和診斷準確性的進步，特別是KCNJ2基因突變的識別，全球安德森-塔維爾症候群市場正在經歷根本性的變化。次世代定序技術的成本降低和處理能力的提升，使臨床醫生能夠快速區分這種罕見的離子通道疾病與其他長QT間期症候群，從而降低誤診率。例如，Illumina公司報告稱，到2024年，其全基因組定序的價格將降至約200美元，這將顯著降低心臟病學領域廣泛基因篩檢的經濟門檻。這種可及性的提高將使更多患者獲得明確的分子診斷，這對於靶向離子通道治療的應用和有效管理心律不整風險至關重要。

此外，支持孤兒藥研發的監管獎勵正在刺激市場活動，並鼓勵製藥公司投資於低發病率疾病的治療方法。監管機構提供必要的支持，例如稅收減免和市場獨佔權，以抵消涉及小樣本患者群體的臨床試驗的巨額成本。根據美國食品藥物管理局（FDA）藥物評估與研究中心於2025年1月發布的《2024年新藥認證報告》，2024年核准的新藥中有52%被認定為孤兒藥，反映了製藥業向罕見疾病領域的策略轉變。美國國家罕見疾病組織（NORD）在2024年報告稱，安德森-塔維爾症候群的發生率約為百萬分之一，如果沒有政府的支持，開發特定治療方法的商業性可行性將受到限制。在此背景下，這種支持性環境至關重要。

市場挑戰

阻礙全球安德森-塔維爾症候群市場發展的主要障礙是臨床實踐中普遍存在的誤診，這主要是由於該疾病症狀的極端多樣性所造成的。患者通常僅表現出部分或特異性症狀，例如心律不整或週期性麻痺，而缺乏特徵性的觀察，導致臨床醫生經常將其誤診為更常見的通道疾病。這種診斷體系的碎片化有效地掩蓋了潛在患者群體的真實規模，阻礙了製藥公司投資研發針對該症候群的藥物，並限制了診斷檢測服務提供者的商機。

快速識別特定KCNJ2基因突變的難度導致合適的治療方法引入系統性延誤。因此，治療經常被推遲，治療重點往往放在控制症狀上，而非解決潛在的遺傳病因。根據美國國家罕見疾病組織（NORD）2025年的數據，複雜罕見疾病患者通常需要經歷3至15年的診斷過程才能獲得準確診斷。這一漫長的過程意味著相當一部分符合條件的患者仍未得到診斷，從而限制了標靶治療的可及性，直接阻礙了市場成長。

市場趨勢

安德森-塔維爾症候群的治療管理正因穿戴式心電圖監測技術的引入而發生革命性變化。這項技術能夠對短暫性心律不整和週期性麻痺進行連續、非侵入性的追蹤。與短期連續型心電圖監測不同，穿戴式裝置能夠長期檢測無症狀事件，使臨床醫生能夠將身體活動與症狀發作聯繫起來，並動態調整治療方案。這一趨勢滿足了症狀波動較大的患者持續監測的迫切需求，並確保不會遺漏兩次就診之間發生的短暫性心率異常。根據美國醫學會 (AMA) 2024 年 3 月發布的一份報告，約 20% 的醫療機構已實施遠端患者監護工具，這表明醫療模式正朝著分散式模式轉變，而這種模式對於複雜通道疾病的管理至關重要。

此外，建立全球協作患者登記庫是一項策略性舉措，旨在整合數據並克服這種超罕見疾病固有的資料碎片化問題。透過收集來自不同國家的自然病程數據，這些登記庫將有助於發現個別病例研究中無法識別的強基因型-表現型相關性，並建立未來治療方法研究所需的臨床終點。這種方法透過確認目標族群規模和疾病進展的基準，降低了藥物研發者的投資風險。 Global Genes 在 2024 年 2 月發布的「2024 NEXT 報告」中指出，其 RARE-X 研究平台已成功招募了來自 83 個不同疾病群體的 8200 多名患者，凸顯了以患者主導的數據舉措在加速安德森-塔維爾症候群等罕見病研究方面日益顯著的成效。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：Andersen-Tawil 症候群的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（1 型、2 型）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：安德森-塔維爾症候群北美市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲安德森-塔維爾症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區安德森-塔維爾症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲安德森-塔維爾症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲安德森-塔維爾症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球安德森-塔維爾症候群市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Novartis AG
  • Mylan NV
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Xeris Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16864

The global market for Andersen-Tawil Syndrome is projected to expand from USD 2.78 billion in 2025 to USD 4.25 billion by 2031, demonstrating a compound annual growth rate of 7.33%. This market primarily includes genetic testing services focused on KCNJ2 mutation detection, alongside therapeutic interventions like anti-arrhythmic drugs and implantable cardioverter-defibrillators. Key drivers for this growth include significant progress in next-generation sequencing technologies, leading to improved diagnostic accuracy, and increased investment in orphan drug development, bolstered by supportive regulatory frameworks. These foundational growth factors signify lasting improvements in identifying and managing the patient population, rather than short-term trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.78 Billion
Market Size 2031USD 4.25 Billion
CAGR 2026-20317.33%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Despite this growth, the market faces a significant obstacle: the high incidence of clinical misdiagnosis. This issue stems from the disorder's wide range of symptoms, which often obscures the actual market size and delays patients' access to necessary treatments. The challenge of accurately stratifying patient risk continues to hinder the broader adoption of therapies. In 2025, data from the European Society of Cardiology revealed that around 11% of diagnosed Andersen-Tawil Syndrome patients suffered life-threatening heart rhythm issues or needed device interventions, underscoring the vital need for more precise diagnostics and tailored treatment strategies.

Market Driver

The global Andersen-Tawil Syndrome market is being fundamentally transformed by improvements in genomic sequencing and diagnostic precision, particularly in identifying KCNJ2 mutations. The reduced expense and enhanced capacity of next-generation sequencing enable clinicians to swiftly distinguish this rare channelopathy from other long QT syndromes, thereby decreasing misdiagnosis rates. For instance, Illumina reported in 2024 that a whole-genome sequence could be provided for about $200, significantly lowering the financial hurdle for extensive genetic screening in cardiology. This increased accessibility ensures more patients receive definitive molecular diagnoses, which is crucial for applying targeted ion channel therapies and effectively managing arrhythmia risks.

Furthermore, supportive regulatory incentives for developing orphan drugs are boosting market activity by encouraging pharmaceutical companies to invest in treatments for conditions with low prevalence. Regulatory agencies offer vital assistance, including tax benefits and market exclusivity, to offset the substantial costs of conducting clinical trials for small patient groups. The FDA Center for Drug Evaluation and Research's January 2025 'New Drug Therapy Approvals 2024' report indicated that 52% of new drugs approved in 2024 were designated as orphan drugs, reflecting a strategic shift in the industry toward rare diseases. This supportive environment is essential given that, as per the National Organization for Rare Disorders in 2024, Andersen-Tawil Syndrome affects approximately one in a million individuals, a statistic that would otherwise limit the commercial feasibility of developing specific treatments without government support.

Market Challenge

A significant obstacle hindering the global Andersen-Tawil Syndrome market is the widespread clinical misdiagnosis, largely due to the disorder's extremely varied symptoms. Patients often present with partial or unusual symptoms, such as only cardiac arrhythmias or periodic paralysis without characteristic physical features, leading clinicians to frequently mistake it for more common channelopathies. This fragmented diagnostic landscape effectively hides the true size of the potential patient base, diminishing pharmaceutical companies' motivation to invest in syndrome-specific drug development and limiting revenue opportunities for diagnostic test providers.

The difficulty in promptly identifying the specific KCNJ2 mutation causes a systemic delay in adopting appropriate therapies. Consequently, treatment is frequently postponed or focused merely on managing symptoms rather than addressing the root genetic cause. Data from the National Organization for Rare Disorders in 2025 showed that individuals with intricate rare conditions typically endure a diagnostic journey of three to fifteen years to receive an accurate diagnosis. This extended period directly impedes market expansion by leaving a considerable portion of eligible patients undiagnosed and thus unable to access targeted therapeutic interventions.

Market Trends

The management of Andersen-Tawil Syndrome is being revolutionized by the adoption of wearable cardiac monitoring technologies, which offer continuous, non-invasive tracking of temporary arrhythmias and periodic paralysis. Unlike brief Holter monitoring, wearables allow for the long-term detection of asymptomatic events, enabling clinicians to link physical activity with symptom onset and dynamically modify treatment plans. This trend addresses the crucial demand for ongoing observation in patients who exhibit significant symptom variability, ensuring that fleeting cardiac irregularities are not overlooked between appointments. A March 2024 report by the American Medical Association indicated that about 20% of physician practices employed remote patient monitoring tools, signifying a move towards decentralized care models vital for managing intricate channelopathies.

Additionally, the creation of collaborative global patient registries is a strategic effort to consolidate data and overcome the inherent fragmentation associated with this ultra-rare condition. By compiling natural history data from various countries, these registries facilitate the discovery of strong genotype-phenotype correlations that cannot be identified through individual case studies, thus establishing the clinical endpoints required for future therapeutic investigations. This method reduces investment risks for pharmaceutical developers by confirming the size of target populations and disease progression benchmarks. Global Genes reported in its February 2024 '2024 NEXT Report' that its RARE-X research platform had successfully registered over 8,200 patients across 83 different disease communities, highlighting the increasing effectiveness of patient-driven data initiatives in expediting research for rare conditions such as Andersen-Tawil Syndrome.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Novartis AG
  • Mylan N.V.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Xeris Pharmaceuticals, Inc.

Report Scope

In this report, the Global Andersen-Tawil Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Andersen-Tawil Syndrome Market, By Disease Type

  • Type 1
  • Type 2

Andersen-Tawil Syndrome Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Andersen-Tawil Syndrome Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Andersen-Tawil Syndrome Market.

Available Customizations:

Global Andersen-Tawil Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Andersen-Tawil Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Type 1, Type 2)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Andersen-Tawil Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Andersen-Tawil Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Andersen-Tawil Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Andersen-Tawil Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Andersen-Tawil Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Andersen-Tawil Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Andersen-Tawil Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Andersen-Tawil Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Andersen-Tawil Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Andersen-Tawil Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Andersen-Tawil Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Andersen-Tawil Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Andersen-Tawil Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Andersen-Tawil Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Andersen-Tawil Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Andersen-Tawil Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Andersen-Tawil Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Andersen-Tawil Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Andersen-Tawil Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Andersen-Tawil Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Andersen-Tawil Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Andersen-Tawil Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Andersen-Tawil Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Andersen-Tawil Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Andersen-Tawil Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Zydus Lifesciences Ltd.
  • 15.5. Novartis AG
  • 15.6. Mylan N.V.
  • 15.7. Aurobindo Pharma Limited
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Viatris Inc.
  • 15.10. Xeris Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer